Trial reportPain research & management2026
Comparison of Liposomal Bupivacaine for Single-Injection Versus Dual-Injection Thoracic Paravertebral Block on Analgesic Effect After Dual-Microport Thoracoscopic Lobectomy: A Prospective Randomized Controlled Trial.
Trial report in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe optimal blockade strategy for thoracic paravertebral block (TPVB) with liposomal bupivacaine (LB) in dual-microport thoracoscopic lobectomy remains unclear. This study evaluated the analgesic efficacy of single-injection versus dual-injection LB in TPVB.
methodsThis prospective randomized controlled trial enrolled patients undergoing elective dual-port thoracoscopic surgery from June to September 2025. Participants were randomly assigned to either a single-injection group (Group S) or a dual-injection group (Group D). Under ultrasound guidance, Group S received a single 20 mL (266 mg) injection of LB at the thoracic vertebrae 4-5, while Group D received two separate 10 mL (133 mg) injections at the thoracic vertebrae 3-4 and 6-7. The primary outcome was the area under the curve (AUC) of the numerical rating scale (NRS) scores during movement over 72 h postoperatively.
resultsA total of 92 patients were included in this study, with 46 patients allocated to each group. The mean AUC (SD) of NRS scores during movement at 72 h postoperatively for Groups S and D was 148.83 (80.18) and 201.52 (111.99) NRS/h, respectively, with a mean difference of 52.69 (95% CI 12.4 to 93.0, p = 0.011). The incidence of chronic pain at 3 months postoperatively was 19.6% in Group S and 21.7% in Group D (p = 0.798). Generalized estimating equation analysis showed that at rest, Group S had lower NRS scores than Group D at 48 h postoperatively (95% CI -1.4 to -0.2, p = 0.044). During movement, the median NRS scores (IQR) at 24 h for Groups S and D were 3.0 (2.0, 3.0) and 3.0 (2.0, 5.0), respectively, with p = 0.009; at 48 h, the median NRS scores (IQR) were 2.0 (1.0, 3.0) and 2.5 (2.0, 5.0), respectively, with p = 0.014. The median block duration (IQR) for Groups S and D was 7.00 (6.00, 8.00) and 11.00 (9.75, 12.00), respectively, with p < 0.01; the median hospital stay (IQR) was 4.00 (3.00, 4.25) and 4.00 (4.00, 5.00), respectively, with p = 0.045.
conclusionSingle-injection LB in TPVB provides comparable or superior analgesic efficacy while significantly reducing the risk of postoperative complications, making it a preferred analgesic strategy.
trial registrationChinese Registry of Clinical Trials: ChiCTR2500104841.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.